Barinthus Biotherapeutics’ Post

I'm excited to share an update on our product candidate for treating Chronic Hepatitis B (VTP-300). Latest results show great promise for this treatment that was summed up well by Prof. Man-Fung Yuen at Queen Mary Hospital, University of Hong Kong: "People with Hepatitis B currently require life-long therapy and may still progress to liver failure or liver cancer, which is a slowly developing and often-devastating process. I'm encouraged by the potential of VTP-300 to provide sustained viral suppression and what may ultimately be a potential functional cure, which would allow patients to stop taking life-long therapies and halt progression of liver failure or cancer.” Full press release here: https://lnkd.in/eW-iiiYB

Live from #ESCCongress 2023: BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk Nicola Ryan reviews this randomized, open-label clinical trial that once again confirms that 1-month #DAPT is confirmed is safe in high-bleeding risk patients https://lnkd.in/d8rRk4fQ #interventionalcardiology

Interesting. Key could be the ability to screen and identify the fibrosis /activity /steatosis of patients in the PCP and ENDO setting so that the patients that are sent have a good reason to be referred. Currently a vast majority of patients sent to specialists by generalists turn out to be F0/F1 with TE/VCTE. That is great for the patient but a diagnostic "failure". Screen more patients and identifying those that have F>2/A>2 = sending a smaller number of patients to a specialist who have a much higher likelihood of needing to be with a specialist

#HappeningNow: In partnership with Incyte, we’re presenting the full results from our AGAVE-201 pivotal trial of axatilimab in patients with chronic GVHD during American Society of Hematology’s #ASH23 Plenary Scientific Session.   We believe that the additional positive data from AGAVE-201 further strengthen axatilimab’s strong safety and efficacy profile as a well-differentiated treatment option for patients with refractory chronic GVHD.   Read the full press release and view the additional data here:  https://bit.ly/3RBczCQ

The latest post-hoc analysis of BLISS-LN by Anders, et al. presents data highlighting the consistent benefit of belimumab versus placebo, when combined with standard therapy, on kidney outcomes. Get all the latest from the world of #Lupus, only on the #LupusForum: https://lnkd.in/dDQbCijZ

Can Understanding HO-1 in BACH1 Knockout Mice Help Treat Sepsis Better? Raghavan Pillai Raju, Medical College of Georgia at Augusta University, USA, will present a short oral contribution during #RedoxMedicine2024 elaborating on this topic. Dr. Raju will discuss  the regulation of HO-1 in BACH1 knockout mice following sepsis. He will provide new insights into the regulatory mechanisms of HO-1 in response to sepsis, potentially informing new therapeutic strategies. Join us on June 27-28, 2024 at Fondation Biermans-Lapôtre, Paris, to learn more! 🔗 Selected Short Orals: https://lnkd.in/gypa9uFD. 🌐 More information: https://lnkd.in/dkNzFQZU. #RedoxMedicieSociety #RedoxMedicine2024 #biomarkers #redoxbiology #redox #antioxidants #innovation #oxidativestress #RedoxResearch

From the latest issue of iGIE: In this Industry Perspective, Barry Slowey and Linda S. Lee ask, "Will the marriage of the interventional endoscopist and hepatologist endure?" Read it at https://lnkd.in/gBM2dM44.

#WorldDuchenneAwareness Day 2023 Theme – #Duchenne: Breaking Barriers People living with Duchenne muscular dystrophy (DMD) face physical, healthcare, and social barriers. This severely limits their ability to participate fully in community life and activities. We at Ardius Pharma make it our priority to provide valuable therapeutic solutions for patients suffering from #RareDiseases

The Passeo-18 Lux DCB’s effectiveness in infra-popliteal arteries is sustained at 24 months, with 0% clinically driven TLRs after 12-month follow-up! 📈 Furthermore, #BTK and non-BTK results had no statistically significant difference, supporting the efficacy of the #Passeo18Lux #DCB when used in below-the-knee arteries. Discover more about the BIOLUX P-III global registry results here: https://ow.ly/Kq6x50PGlZk #Endovascular

Hello Everyone, Yesterday, I went on Arise news to discuss the outputs of the Federal Ministry of Health and Social Weldfare’s recent Minesterial briefing and the progress our ministry has made in the last nine-months under President Tinubu in regards to the rising cost of pharmaceuticals, medical brain drain, primary health care centre improvements, cancer care and more. Click the link below to watch the full interview: https://lnkd.in/gUpnipQq